Evidence map›Paper›PMID 27405645›Full record

ArticleAbdominal radiology (New York)2016

FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal-gastric junction.

Pavel Fencl, Otakar Belohlavek, Tomas Harustiak, Milada Zemanova

Open access · hybridAbstract read
In one paragraph

Article in Abdominal radiology (New York), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Pavel FenclPET Center, Hospital Na Homolce, Roentgenova 2, 150 30, Prague 5, Czech Republic. pavel.fencl@homolka.cz.
Otakar BelohlavekPET Center, Hospital Na Homolce, Roentgenova 2, 150 30, Prague 5, Czech Republic.
Tomas Harustiak3rd Clinic of Surgery, First Faculty of Medicine, Charles University in Prague and University Hospital Motol, V Uvalu 84, Praha 5, 150 06, Czech Republic.
Milada ZemanovaClinic of Oncology, First Faculty of Medicine, Charles University in Prague and General Teaching Hospital, U Nemocnice 2, Praha 2, 128 08, Czech Republic.
Charles University · CZNa Homolce Hospital · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe aim of the analysis was to assess the accuracy of various FDG-PET/CT parameters in staging lymph nodes after neoadjuvant chemotherapy.

methodsIn this prospective study, 74 patients with adenocarcinoma of the esophageal-gastric junction were examined by FDG-PET/CT in the course of their neoadjuvant chemotherapy given before surgical treatment. Data from the final FDG-PET/CT examinations were compared with the histology from the surgical specimens (gold standard). The accuracy was calculated for four FDG-PET/CT parameters: (1) hypermetabolic nodes, (2) large nodes, (3) large-and-medium large nodes, and (4) hypermetabolic or large nodes.

resultsIn 74 patients, a total of 1540 lymph nodes were obtained by surgery, and these were grouped into 287 regions according to topographic origin. Five hundred and two nodes were imaged by FDG-PET/CT and were grouped into these same regions for comparison. In the analysis, (1) hypermetabolic nodes, (2) large nodes, (3) large-and-medium large nodes, and (4) hypermetabolic or large nodes identified metastases in particular regions with sensitivities of 11.6%, 2.9%, 21.7%, and 13.0%, respectively; specificity was 98.6%, 94.5%, 74.8%, and 93.6%, respectively. The best accuracy of 77.7% reached the parameter of hypermetabolic nodes. Accuracy decreased to 62.0% when also smaller nodes (medium-large) were taken for the parameter of metastases.

conclusionsFDG-PET/CT proved low sensitivity and high specificity. Low sensitivity was based on low detection rate (32.6%) when compared nodes imaged by FDG-PET/CT to nodes found by surgery, and in inability to detect micrometastases. Sensitivity increased when also medium-large LNs were taken for positive, but specificity and accuracy decreased.

Indexed as

Positron Emission Tomography Computed TomographyAdenocarcinomaAdultAgedChemotherapy, AdjuvantEsophageal NeoplasmsEsophagogastric JunctionFemaleFluorodeoxyglucose F18HumansLymphatic MetastasisMaleMiddle AgedNeoadjuvant TherapyNeoplasm StagingProspective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsAccuracyEsophageal adenocarcinomaFDG-PET/CTNeoadjuvant chemotherapyNodal staging

Identifiers

PMID27405645
PMCPMC5059406
OpenAlexW2463112833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.